Skip to content

CBD-SIB - Efficacy of cannabidiol in the management of Self-Injurious Behavior in children and adolescents with severe neurodevelopmental disorders

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-521161-27-00
Acronym
APHP240090
Enrollment
21
Registered
2025-10-07
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Children and adolescents with severe neurodevelopmental disorders

Brief summary

Cannabidiol will be considered effective at V8 D56 in clinically significant reductions in the frequency of self-injuries if the frequency score on the “Self-Injurious Behavior” subdomain of the BPI-01 is reduced by 30% or more at visit V8 D56 compared to visit V2 D0.

Detailed description

Cannabidiol will be considered effective at V6 D31 to clinically significantly reduce the frequency of self-injuries if the frequency score in the BPI-01 “Self-injurious Behavior” subdomain is reduced by 30% or more at visit V6 D31 compared to visit V2 D0., efficacy of the treatment assessed by the change in percentage scores between visit V2 D0 and visits V6 D31 and V8 D56: in the BPI-01 “Self-injurious behavior” subdomain; “Stereotyped behaviors” subdomain;“Aggressive/Destructive Behaviors” subdomain;- GED-DI score;- QI-Disability score;- Parental Stress Scale (PSS) score., Serious and non-serious clinical adverse events, in particular: diarrhea, vomiting, decreased appetite, weight loss, drowsiness, asthenia, fever, increased transaminases or total bilirubin, decreased hemoglobin and hematocrit, increased creatinine., Correlation between the change in the frequency of self-injuries (frequency score in the “Self-injurious behavior” subdomain of the BPI-01) between V2 D0 and V6 D31 and V8 D56 and the change in the frequency of non-verbal manifestations of pain (GED-DI score) between V2 D0 and V6 D31 and V8 D56

Interventions

Sponsors

Assistance Publique Hopitaux De Paris
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
Cannabidiol will be considered effective at V8 D56 in clinically significant reductions in the frequency of self-injuries if the frequency score on the “Self-Injurious Behavior” subdomain of the BPI-01 is reduced by 30% or more at visit V8 D56 compared to visit V2 D0.

Secondary

MeasureTime frame
Cannabidiol will be considered effective at V6 D31 to clinically significantly reduce the frequency of self-injuries if the frequency score in the BPI-01 “Self-injurious Behavior” subdomain is reduced by 30% or more at visit V6 D31 compared to visit V2 D0., efficacy of the treatment assessed by the change in percentage scores between visit V2 D0 and visits V6 D31 and V8 D56: in the BPI-01 “Self-injurious behavior” subdomain; “Stereotyped behaviors” subdomain;“Aggressive/Destructive Behaviors” subdomain;- GED-DI score;- QI-Disability score;- Parental Stress Scale (PSS) score., Serious and non-serious clinical adverse events, in particular: diarrhea, vomiting, decreased appetite, weight loss, drowsiness, asthenia, fever, increased transaminases or total bilirubin, decreased hemoglobin and hematocrit, increased creatinine., Correlation between the change in the frequency of self-injuries (frequency score in the “Self-injurious behavior” subdomain of the BPI-01) between V2 D0 and V6 D31 an

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026